2024 Phase 2 trial of eRapa by Biodexa Pharmaceuticals shows potential for managing precancerous polyps in FAP patients, a genetic condition linked to colorectal cancer.
Biodexa Pharmaceuticals, a UK-based biopharmaceutical company, reports additional positive results from a Phase 2 trial of eRapa, a potential treatment for Familial Adenomatous Polyposis (FAP). FAP is a genetic condition linked to colorectal cancer. The trial, presented at the 2024 InSIGHT meeting, shows eRapa's potential for managing precancerous polyps in the GI tract, as no approved therapeutic options exist for FAP patients.
July 11, 2024
3 Articles